Single Sample hs Troponin Evaluation (≥3 Hours Symptom) Tool

Clinical calculation support · Verify results before clinical use

Patient and assay inputs

Enter the measured hs-cTn concentration and the assay-specific reference thresholds.

Single sample · ≥3 h
Use the reported value from the laboratory.
Use the correct assay- and, where applicable, sex-specific URL.
Obtain from the validated pathway for the exact assay. Do not substitute the 99th-percentile URL unless the pathway explicitly specifies it.
A single-sample strategy should not be used for early presenters with symptoms under 3 hours.
ECG and clinical assessment are required; troponin must not override an ischemic ECG.
Important: This tool provides a structured interpretation, not an independent diagnosis. A value below the 99th-percentile URL alone is not sufficient for a single-sample MI rule-out. Use only validated assay-specific thresholds within a clinical decision pathway.

Clinical context

High-sensitivity cardiac troponin (hs-cTn) is used to detect myocardial injury in patients with suspected acute coronary syndrome. The 99th-percentile URL is assay-specific and identifies myocardial injury; an elevated value does not, by itself, establish myocardial infarction.

How to interpret this tool

  • Symptoms under 3 hours: do not use a single sample to rule out MI; follow a validated serial hs-cTn pathway.
  • At or above the 99th-percentile URL: evaluate for myocardial injury and determine whether there is a rise/fall pattern and evidence of ischemia.
  • Below the URL but above the validated single-sample cutoff: this tool does not classify the patient as ruled out; serial testing and clinical assessment are required.
  • At or below a validated single-sample cutoff: this may support rule-out only with appropriate symptom timing, a nonischemic ECG, low-risk clinical assessment, and use of the exact assay-specific pathway.

Safety reminders

Do not use troponin alone to exclude ACS. Consider symptom characteristics, haemodynamic status, ECG findings, alternative causes of myocardial injury, and local protocols. Do not delay urgent treatment for suspected STEMI while awaiting biomarkers.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
J Am Coll Cardiol. 2025. Describes hs-cTn use, assay-specific 99th-percentile URL, serial testing, and symptom timing. Official guideline.
Kontos MC, de Lemos JA, Deitelzweig SB, et al. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department.
J Am Coll Cardiol. 2022;80:1925–1960. DOI: 10.1016/j.jacc.2022.08.750. Recommends a conservative ≥3-hour symptom-onset criterion and describes assay-specific very-low thresholds and the limitations of URL-only 0/3-hour strategies. Full text.
Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain.
Circulation. 2021. Supports use of hs-cTn and careful consideration of symptom timing and assay characteristics. Official guideline.
Clinical disclaimer: This tool supports, but does not replace, clinical judgement or local ACS protocols. Single-sample rule-out is appropriate only for selected patients and validated assay-specific pathways. Persistent or recurrent symptoms, an ischemic ECG, haemodynamic instability, or high clinical suspicion requires further urgent assessment regardless of this output.